B · Normal
[Fosun Pharma: Several drugs are newly included in the National Reimbursement Catalog] On November 15th, Fosun Pharma (600196.SH) announced that according to the 2026 National Reimbursement Catalog, a number of products of the company and its holding subsidiaries have been included for the first time, and the remark information has been adjusted or transferred to regular catalog management. Among them, slulimab injection was included for the first time, Vovesicil Citrate Capsules and Ruwometinib Tablets had new payment indications, and anti-human T-cell rabbit immunoglobulin relaxed payment restrictions.
Comments